Metraipolis › archive › dc_2f5cd662fc39

Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study — Europe PMC PMID:41039909

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41039909
DOI
10.1111/cts.70373
License (as archived)
solo-consultazione
Archived
2026-11-09T16:14:24.568Z
SHA-256 of the archived text
c9536d81d7dd438b203478c5d23db4c19d7e43362083a126acd45c063b2b447c
Stable URL of this page
https://metraipolis.com/documento/dc_2f5cd662fc39

How to cite

Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study — Europe PMC PMID:41039909 — Europe PMC (en), https://europepmc.org/article/MED/41039909 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2f5cd662fc39 (Metraipolis archive dc_2f5cd662fc39, sha256 c9536d81d7dd438b203478c5d23db4c19d7e43362083a126acd45c063b2b447c)
BibTeX
@misc{dc2f5cd662fc39,
  title = {Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study — Europe PMC PMID:41039909},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41039909},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2f5cd662fc39; sha256 c9536d81d7dd438b203478c5d23db4c19d7e43362083a126acd45c063b2b447c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41039909. Agents can read the archived copy with the MCP tool read_document.